ACAD:NSD-ACADIA Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 55.86

Change

+1.14 (+2.08)%

Market Cap

USD 8.70B

Volume

1.27M

Average Target Price

USD 55.56 (-0.53%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.60 (+0.74%)

USD56.30B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

+2.21 (+0.44%)

USD54.00B 20.76 16.02
MRNA Moderna, Inc

+10.62 (+10.78%)

USD39.00B N/A N/A
SGEN Seagen Inc

+0.82 (+0.50%)

USD29.47B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

-0.18 (-0.15%)

USD26.94B 28.36 26.40
RPRX Royalty Pharma plc

+1.39 (+3.51%)

USD24.75B 23.05 9.48
BNTX BioNTech SE

+3.09 (+3.03%)

USD24.53B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.98 (+3.11%)

USD23.81B N/A N/A
GMAB Genmab A/S

+0.68 (+1.93%)

USD23.24B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ACAD

Symbol Name Weight Mer Price(Change) Market Cap
CHEP AGFiQ U.S. Market Neutral.. 0.00 % 1.61 %

-0.19 (-1.17%)

USD0.70M
MOM AGFiQ U.S. Market Neutral.. 0.00 % 2.32 %

+0.58 (+2.45%)

USD6.07M
SIZ AGFiQ U.S. Market Neutral.. 0.00 % 2.82 %

N/A

USD0.88M
AGED:LSE iShares Ageing Population.. 0.00 % 0.40 %

-0.04 (-0.57%)

USD0.27B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.40 %

-5.88 (-0.85%)

USD1.46B
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.40 %

-0.06 (-0.63%)

USD1.53B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.58% 65% D 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.58% 65% D 73% C
Trailing 12 Months  
Capital Gain 18.85% 52% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.85% 52% F 64% D
Trailing 5 Years  
Capital Gain 42.50% 75% C 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.50% 75% C 59% F
Average Annual (5 Year Horizon)  
Capital Gain 23.32% N/A N/A 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.32% N/A N/A 80% B-
Risk Return Profile  
Volatility (Standard Deviation) 59.80% N/A N/A 18% F
Risk Adjusted Return 38.99% N/A N/A 61% D-
Market Capitalization 8.70B 96% A 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 13.00 11% F 9% F
Price / Cash Flow Ratio -57.56 94% A 94% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -39.86% 70% C- 25% F
Return on Invested Capital -42.00% 71% C- 22% F
Return on Assets -17.86% 71% C- 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 9.25 28% F 16% F
Short Percent 9.69% 34% F 23% F
Beta 1.43 54% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector